"Antiparkinson Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
| Descriptor ID |
D000978
|
| MeSH Number(s) |
D27.505.954.427.090.050
|
| Concept/Terms |
Antiparkinson Agents- Antiparkinson Agents
- Agents, Antiparkinson
- Antiparkinsonian Agents
- Agents, Antiparkinsonian
- Antiparkinsonians
- Antiparkinson Drugs
- Drugs, Antiparkinson
|
Below are MeSH descriptors whose meaning is more general than "Antiparkinson Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiparkinson Agents".
This graph shows the total number of publications written about "Antiparkinson Agents" by people in this website by year, and whether "Antiparkinson Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 0 | 2 | 2 |
| 2017 | 14 | 8 | 22 |
| 2018 | 14 | 6 | 20 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Antiparkinson Agents" by people in Profiles.
-
Care of Parkinson's disease (PD) patients in times of covid-19 pandemic. Diabetes Metab Syndr. 2021 Jul-Aug; 15(4):102168.
-
Analysis of nationwide multimodal complex treatment and drug pump therapy in Parkinson's disease in times of COVID-19 pandemic in Germany. Parkinsonism Relat Disord. 2021 04; 85:109-113.
-
[Amantadine in the treatment of Parkinson's disease. New opportunities in the context of COVID-19]. Zh Nevrol Psikhiatr Im S S Korsakova. 2021; 121(4):101-106.
-
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update. J Parkinsons Dis. 2021; 11(3):891-903.
-
Parkinson's Disease and the COVID-19 Pandemic. J Parkinsons Dis. 2021; 11(2):431-444.
-
COVID-19 and Parkinson's Disease: What Do We Know So Far? J Parkinsons Dis. 2021; 11(2):445-454.
-
Targeting COVID-19 in Parkinson's Patients: Drugs Repurposed. Curr Med Chem. 2021; 28(12):2392-2408.
-
Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials. Trials. 2020 Dec 22; 21(1):1028.
-
SARS-CoV-2 infection in patients with serious mental illness and possible benefits of prophylaxis with Memantine and Amantadine. Rom J Morphol Embryol. 2020 Oct-Dec; 61(4):1007-1022.
-
Predictors of COVID-19 outcome in Parkinson's disease. Parkinsonism Relat Disord. 2020 09; 78:134-137.